مورد إلكتروني
Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study.
| العنوان: | Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. |
|---|---|
| المؤلفون: | Lane, Jennifer CE |
| بيانات النشر: | eScholarship, University of California 2020-12-25 |
| تفاصيل مُضافة: | Lane, Jennifer CE Weaver, James Kostka, Kristin Duarte-Salles, Talita Abrahao, Maria Tereza F Alghoul, Heba Alser, Osaid Alshammari, Thamir M Areia, Carlos Biedermann, Patricia Banda, Juan M Burn, Edward Casajust, Paula Fister, Kristina Hardin, Jill Hester, Laura Hripcsak, George Kaas-Hansen, Benjamin Skov Khosla, Sajan Kolovos, Spyros Lynch, Kristine E Makadia, Rupa Mehta, Paras P Morales, Daniel R Morgan-Stewart, Henry Mosseveld, Mees Newby, Danielle Nyberg, Fredrik Ostropolets, Anna Woong Park, Rae Prats-Uribe, Albert Rao, Gowtham A Reich, Christian Rijnbeek, Peter Sena, Anthony G Shoaibi, Azza Spotnitz, Matthew Vignesh, Subbian Suchard, Marc A Vizcaya, David Wen, Haini de Wilde, Marcel Xie, Junqing You, Seng Chan Zhang, Lin Lovestone, Simon Ryan, Patrick Prieto-Alhambra, Daniel OHDSI-COVID-19 consortium |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | ObjectivesConcern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.MethodsWe performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HRs), with estimates pooled where I2 <40%.ResultsA total of 918 144 and 290 383 users of HCQ and SSZ, respectively, were included. No consistent risk of psychiatric events was observed with short-term HCQ (compared with SSZ) use, with meta-analytic HRs of 0.96 (95% CI 0.79, 1.16) for depression, 0.94 (95% CI 0.49, 1.77) for suicide/suicidal ideation and 1.03 (95% CI 0.66, 1.60) for psychosis. No consistent long-term risk was seen, with meta-analytic HRs of 0.94 (95% CI 0.71, 1.26) for depression, 0.77 (95% CI 0.56, 1.07) for suicide/suicidal ideation and 0.99 (95% CI 0.72, 1.35) for psychosis.ConclusionHCQ as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation or psychosis compared with SSZ. No effects were seen in the short or long term. Use at a higher dose or for different indications needs further investigation.Trial registrationRegistered with EU PAS (reference no. EUPAS34497; http://www.encepp.eu/encepp/viewResource.htm? id=34498). The full study protocol and analysis source code can be found at htt |
| مصطلحات الفهرس: | OHDSI-COVID-19 consortium, HCQ, depression, epidemiology, RA, psychosis, safety, Arthritis & Rheumatology, Clinical Sciences, Immunology, Public Health and Health Services, publication |
| URL: | |
| الإتاحة: | Open access content. Open access content public |
| ملاحظة: | application/pdf |
| أرقام أخرى: | CDLER oai:escholarship.org/ark:/13030/qt85p0k239 qt85p0k239 https://escholarship.org/uc/item/85p0k239 https://escholarship.org/ 1245252716 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1245252716 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |